Unlabelled: Glucocorticoid-induced osteoporosis (GIOP) is a common condition associated with increased risk for fracture. Many patients receive suboptimal care. We created a novel GIOP clinic model which successfully fills a gap in osteoporosis care by providing multidisciplinary intervention in key components of GIOP preventive care to an underserved patient population.

Introduction: This study characterizes the patient population referred to our novel glucocorticoid-induced osteoporosis (GIOP) clinic and evaluates how well the clinic performed in addressing key components of GIOP preventive care.

Methods: This population-based prospective cohort study derives data from patients reviewed at the University of Alberta Multidisciplinary Bone Health Clinic from January 2017 to September 2019. To create our clinic model, key components of GIOP preventive care were summarized based on current guidelines, and clear responsibilities were delegated to each multidisciplinary team member. A REDCap database was constructed, and each patient's multidisciplinary assessment was entered at each visit. Demographic and treatment data was extracted from our database.

Results: The clinic was able to achieve optimal GIOP preventive care in 60.1% of patients and in 78.7% of patients when excluding wait time. Of the 245 GIOP patients assessed, over half were females (56.7%) and the mean age was 56.7 years (range 16-95 years). Referrals were primarily made by specialists. Low-trauma fractures were reported in 24.9% of patients and 95.5% of patients had a baseline dual-energy X-ray absorptiometry (DXA). The mean current daily prednisone-equivalent dose was 14.1 mg. All patients received a recommendation for pharmacotherapy (100%) and the majority received counseling on vitamin D (98.8%), calcium (97.8%), smoking cessation (98.8%), alcohol reduction (98.4%), falls prevention (88.6%), and exercise (85.3%).

Conclusion: Our novel GIOP clinic model successfully fills a gap in osteoporosis care by providing multidisciplinary intervention in key components of GIOP preventive care to an underserved patient population. Further studies are required to assess the real-world long-term outcomes of our model.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11657-021-00979-6DOI Listing

Publication Analysis

Top Keywords

giop preventive
20
key components
16
components giop
16
preventive care
16
glucocorticoid-induced osteoporosis
12
giop clinic
12
clinic model
12
giop
10
patients
9
multidisciplinary bone
8

Similar Publications

Background: The increasing prevalence of glucocorticoid-induced osteoporosis (GIOP) due to long-term glucocorticoid therapy underscores the need for effective treatment options. Denosumab and bisphosphonates, both key in managing GIOP, require further comparative evaluation to determine their relative efficacy and safety profiles.

Methods: We conducted a systematic review and meta-analysis, adhering to PRISMA guidelines.

View Article and Find Full Text PDF
Article Synopsis
  • - The report by the European Calcified Tissue Society (ECTS) outlines evidence-based recommendations for preventing and treating glucocorticoid-induced osteoporosis (GIOP) in adults, aimed at healthcare providers who may not specialize in bone health.
  • - Experts reviewed the literature and created 25 recommendations that categorize patients based on their fracture risk: medium, high, and very high, considering factors like age and history of fractures for appropriate treatment strategy.
  • - Key general measures include optimizing calcium and vitamin D intake, assessing fracture risk regularly for those on glucocorticoids for three months or longer, and minimizing fall risks among patients.
View Article and Find Full Text PDF

Glucocorticoid-induced osteoporosis (GIOP) is the leading cause of iatrogenic osteoporosis due to the widespread clinical use of glucocorticoids (GC) as immunosuppressants. Previous research identified the proline-rich tyrosine kinase 2, Pyk2, as a critical mediator of GC-induced bone loss, and that blocking Pyk2 could protect the skeleton from adverse GC actions. However, systemic administration of current Pyk2 inhibitors causes harmful side effects, such as skin lesions.

View Article and Find Full Text PDF
Article Synopsis
  • Glucocorticoid-induced osteoporosis (GIOP) complicates dental implant success, and the study investigates the role of Eldecalcitol (ED-71) in improving osseointegration under such conditions.
  • A rat model of GIOP was used, with mini-implants surgically placed, while ED-71 was administered to examine its effect on bone remodeling and implant integration.
  • Results showed that ED-71 enhanced new bone formation and reduced inflammation around implants, working through the sirtuin 1 (SIRT1) pathway and affecting key signaling pathways related to bone health.
View Article and Find Full Text PDF
Article Synopsis
  • This study examines the osteogenic effects of soybean peptide VVELLKAFEEKF (SOP) and its relationship with TGF-β1 in promoting bone cell activity.
  • SOP encourages proliferation, differentiation, and mineralization of osteoblasts in a dose-dependent manner through the activation of specific signaling pathways (p38-MAPK and Smad2/3).
  • Additionally, SOP has shown potential in improving bone density and function in glucocorticoid-induced osteoporosis models in zebrafish, suggesting its possible use as a functional food to combat osteoporosis.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!